A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma - Regional Cancer Care Associates LLC

Clinical Trials

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma
Locations
Hackensack
Sponsor
Cleave Bioscience
Protocol Number
CLC-102
Cancer Diagnosis
To Learn More Call
201-510-0910